JP4944611B2 - ニューロンの成長を調節する化合物およびそれらの使用 - Google Patents

ニューロンの成長を調節する化合物およびそれらの使用 Download PDF

Info

Publication number: JP4944611B2
Authority: JP; Japan
Prior art keywords: cyclic peptide; trk; peptide; receptor; amino acid
Prior art date: 2003-09-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP2006526381A

Other languages

English (en)

Japanese (ja)

Other versions

JP2007505145A (ja

JP2007505145A5 (2

Inventor

パトリック・ドハーティ

ギャレス・ウィリアムズ

Original Assignee

キングズカレッジロンドン

ワイス・エルエルシー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-10

Filing date

2004-09-10

Publication date

2012-06-06

2004-09-10 Application filed by キングズカレッジロンドン, ワイス・エルエルシー filed Critical キングズカレッジロンドン

2007-03-08 Publication of JP2007505145A publication Critical patent/JP2007505145A/ja

2007-06-07 Publication of JP2007505145A5 publication Critical patent/JP2007505145A5/ja

2012-06-06 Application granted granted Critical

2012-06-06 Publication of JP4944611B2 publication Critical patent/JP4944611B2/ja

2024-09-10 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 title claims description 115
230000007514 neuronal growth Effects 0.000 title claims description 33
108010069514 Cyclic Peptides Proteins 0.000 claims description 203
102000001189 Cyclic Peptides Human genes 0.000 claims description 203
238000000034 method Methods 0.000 claims description 164
230000000694 effects Effects 0.000 claims description 141
210000004027 cell Anatomy 0.000 claims description 108
230000002401 inhibitory effect Effects 0.000 claims description 106
230000014511 neuron projection development Effects 0.000 claims description 102
230000004044 response Effects 0.000 claims description 75
150000001413 amino acids Chemical class 0.000 claims description 73
230000001404 mediated effect Effects 0.000 claims description 73
210000003169 central nervous system Anatomy 0.000 claims description 66
235000001014 amino acid Nutrition 0.000 claims description 64
229940024606 amino acid Drugs 0.000 claims description 62
125000000539 amino acid group Chemical group 0.000 claims description 48
230000012010 growth Effects 0.000 claims description 47
239000003112 inhibitor Substances 0.000 claims description 34
239000003814 drug Substances 0.000 claims description 21
230000008439 repair process Effects 0.000 claims description 20
239000008194 pharmaceutical composition Substances 0.000 claims description 19
230000006576 neuronal survival Effects 0.000 claims description 16
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 claims description 15
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 claims description 15
108010077641 Nogo Proteins Proteins 0.000 claims description 14
102000010410 Nogo Proteins Human genes 0.000 claims description 14
108091007960 PI3Ks Proteins 0.000 claims description 14
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims description 14
210000004899 c-terminal region Anatomy 0.000 claims description 14
125000004122 cyclic group Chemical group 0.000 claims description 14
230000003956 synaptic plasticity Effects 0.000 claims description 14
230000003376 axonal effect Effects 0.000 claims description 11
235000018417 cysteine Nutrition 0.000 claims description 11
-1 GT1b Proteins 0.000 claims description 10
125000000524 functional group Chemical group 0.000 claims description 10
238000012216 screening Methods 0.000 claims description 10
108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 claims description 9
239000000969 carrier Substances 0.000 claims description 9
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 9
238000000338 in vitro Methods 0.000 claims description 9
AUFHLLPVPSMEOG-YUMQZZPRSA-N Arg-Gly-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O AUFHLLPVPSMEOG-YUMQZZPRSA-N 0.000 claims description 8
108010005298 Oligodendrocyte-Myelin Glycoprotein Proteins 0.000 claims description 7
102100026746 Oligodendrocyte-myelin glycoprotein Human genes 0.000 claims description 7
239000003085 diluting agent Substances 0.000 claims description 7
230000001105 regulatory effect Effects 0.000 claims description 7
230000002708 enhancing effect Effects 0.000 claims description 6
RMVRSNDYEFQCLF-UHFFFAOYSA-N phenyl mercaptan Natural products SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 claims description 6
239000004472 Lysine Substances 0.000 claims description 5
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 5
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
125000003047 N-acetyl group Chemical group 0.000 claims description 4
125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 4
ZONXBXMWKSOXCA-RXMQYKEDSA-N (2r)-2-sulfanylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@]1(S)CCCN1 ZONXBXMWKSOXCA-RXMQYKEDSA-N 0.000 claims description 3
LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 3
DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 claims description 3
102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 claims description 3
108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 claims description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
102000014105 Semaphorin Human genes 0.000 claims description 3
108050003978 Semaphorin Proteins 0.000 claims description 3
229940009098 aspartate Drugs 0.000 claims description 3
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
229960001639 penicillamine Drugs 0.000 claims description 3
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims 4
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 2
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
108010091748 peptide A Proteins 0.000 claims 1
108090000765 processed proteins & peptides Proteins 0.000 description 260
108010025020 Nerve Growth Factor Proteins 0.000 description 192
210000002569 neuron Anatomy 0.000 description 132
239000000816 peptidomimetic Substances 0.000 description 119
102000007072 Nerve Growth Factors Human genes 0.000 description 112
239000003795 chemical substances by application Substances 0.000 description 109
102000004196 processed proteins & peptides Human genes 0.000 description 104
108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 90
102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 90
229940077737 brain-derived neurotrophic factor Drugs 0.000 description 84
102000015336 Nerve Growth Factor Human genes 0.000 description 79
229940053128 nerve growth factor Drugs 0.000 description 78
108090000099 Neurotrophin-4 Proteins 0.000 description 75
238000002474 experimental method Methods 0.000 description 75
239000011230 binding agent Substances 0.000 description 71
102000003683 Neurotrophin-4 Human genes 0.000 description 64
230000027455 binding Effects 0.000 description 54
239000002609 medium Substances 0.000 description 51
229920001184 polypeptide Polymers 0.000 description 51
239000000556 agonist Substances 0.000 description 48
239000000203 mixture Substances 0.000 description 43
230000002490 cerebral effect Effects 0.000 description 42
108010013731 Myelin-Associated Glycoprotein Proteins 0.000 description 39
102000017099 Myelin-Associated Glycoprotein Human genes 0.000 description 39
239000005557 antagonist Substances 0.000 description 35
102000005962 receptors Human genes 0.000 description 35
108020003175 receptors Proteins 0.000 description 35
239000003446 ligand Substances 0.000 description 33
125000003275 alpha amino acid group Chemical group 0.000 description 28
239000013078 crystal Substances 0.000 description 28
108090000742 Neurotrophin 3 Proteins 0.000 description 27
230000008569 process Effects 0.000 description 26
238000012360 testing method Methods 0.000 description 26
102000000905 Cadherin Human genes 0.000 description 25
108050007957 Cadherin Proteins 0.000 description 25
102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 description 24
239000000018 receptor agonist Substances 0.000 description 24
229940044601 receptor agonist Drugs 0.000 description 24
108050000637 N-cadherin Proteins 0.000 description 23
102100029268 Neurotrophin-3 Human genes 0.000 description 23
101150056950 Ntrk2 gene Proteins 0.000 description 23
230000004048 modification Effects 0.000 description 23
238000012986 modification Methods 0.000 description 23
239000001963 growth medium Substances 0.000 description 22
102000004169 proteins and genes Human genes 0.000 description 22
108090000623 proteins and genes Proteins 0.000 description 22
102000006386 Myelin Proteins Human genes 0.000 description 21
108010083674 Myelin Proteins Proteins 0.000 description 21
125000005647 linker group Chemical group 0.000 description 21
210000005012 myelin Anatomy 0.000 description 21
210000002241 neurite Anatomy 0.000 description 21
235000018102 proteins Nutrition 0.000 description 21
239000000126 substance Substances 0.000 description 20
238000003556 assay Methods 0.000 description 19
230000015572 biosynthetic process Effects 0.000 description 19
230000006870 function Effects 0.000 description 19
230000008685 targeting Effects 0.000 description 19
101150111783 NTRK1 gene Proteins 0.000 description 18
238000009472 formulation Methods 0.000 description 18
210000001519 tissue Anatomy 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
102100033986 Neurotensin receptor type 1 Human genes 0.000 description 16
229940079593 drug Drugs 0.000 description 16
101000979249 Homo sapiens Neuromodulin Proteins 0.000 description 15
102100023206 Neuromodulin Human genes 0.000 description 15
238000007363 ring formation reaction Methods 0.000 description 15
238000011282 treatment Methods 0.000 description 15
108091003079 Bovine Serum Albumin Proteins 0.000 description 14
238000005481 NMR spectroscopy Methods 0.000 description 14
239000012634 fragment Substances 0.000 description 14
150000008574 D-amino acids Chemical class 0.000 description 13
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 13
238000006243 chemical reaction Methods 0.000 description 13
239000012894 fetal calf serum Substances 0.000 description 13
238000001727 in vivo Methods 0.000 description 13
230000005764 inhibitory process Effects 0.000 description 13
230000003993 interaction Effects 0.000 description 13
229920005989 resin Polymers 0.000 description 13
239000011347 resin Substances 0.000 description 13
239000002356 single layer Substances 0.000 description 13
238000003786 synthesis reaction Methods 0.000 description 13
241001465754 Metazoa Species 0.000 description 12
102000038030 PI3Ks Human genes 0.000 description 12
125000003277 amino group Chemical group 0.000 description 12
238000004458 analytical method Methods 0.000 description 12
230000001965 increasing effect Effects 0.000 description 12
239000000178 monomer Substances 0.000 description 12
229940044551 receptor antagonist Drugs 0.000 description 12
239000002464 receptor antagonist Substances 0.000 description 12
238000011084 recovery Methods 0.000 description 12
230000011664 signaling Effects 0.000 description 12
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 11
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 11
101150117329 NTRK3 gene Proteins 0.000 description 11
102100033857 Neurotrophin-4 Human genes 0.000 description 11
238000003501 co-culture Methods 0.000 description 11
238000013461 design Methods 0.000 description 11
239000000463 material Substances 0.000 description 11
238000005016 nuclear Overhauser enhanced spectroscopy Methods 0.000 description 11
239000000243 solution Substances 0.000 description 11
102000003886 Glycoproteins Human genes 0.000 description 10
108090000288 Glycoproteins Proteins 0.000 description 10
150000008575 L-amino acids Chemical class 0.000 description 10
239000003153 chemical reaction reagent Substances 0.000 description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
230000001737 promoting effect Effects 0.000 description 10
208000020431 spinal cord injury Diseases 0.000 description 10
238000002560 therapeutic procedure Methods 0.000 description 10
150000003573 thiols Chemical class 0.000 description 10
108010064880 trkB Receptor Proteins 0.000 description 10
102000015534 trkB Receptor Human genes 0.000 description 10
102000016359 Fibronectins Human genes 0.000 description 9
108010067306 Fibronectins Proteins 0.000 description 9
108010039918 Polylysine Proteins 0.000 description 9
229940044572 TrkB antagonist Drugs 0.000 description 9
230000028600 axonogenesis Effects 0.000 description 9
230000009286 beneficial effect Effects 0.000 description 9
238000010168 coupling process Methods 0.000 description 9
238000010790 dilution Methods 0.000 description 9
239000012895 dilution Substances 0.000 description 9
231100000673 dose–response relationship Toxicity 0.000 description 9
239000011159 matrix material Substances 0.000 description 9
229920000656 polylysine Polymers 0.000 description 9
230000001225 therapeutic effect Effects 0.000 description 9
PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 8
TUSCYCAIGRVBMD-UHFFFAOYSA-N ANA-12 Chemical compound C=1C2=CC=CC=C2SC=1C(=O)NC1=CC=CC=C1C(=O)NC1CCCCNC1=O TUSCYCAIGRVBMD-UHFFFAOYSA-N 0.000 description 8
102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 8
101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 8
239000012655 TrkB antagonist Substances 0.000 description 8
238000005859 coupling reaction Methods 0.000 description 8
239000000539 dimer Substances 0.000 description 8
210000002966 serum Anatomy 0.000 description 8
238000006467 substitution reaction Methods 0.000 description 8
238000013268 sustained release Methods 0.000 description 8
239000012730 sustained-release form Substances 0.000 description 8
108091035707 Consensus sequence Proteins 0.000 description 7
241000124008 Mammalia Species 0.000 description 7
241000700159 Rattus Species 0.000 description 7
102100029826 Reticulon-4 receptor Human genes 0.000 description 7
101710093481 Reticulon-4 receptor Proteins 0.000 description 7
150000001408 amides Chemical class 0.000 description 7
239000000427 antigen Substances 0.000 description 7
108091007433 antigens Proteins 0.000 description 7
102000036639 antigens Human genes 0.000 description 7
125000004429 atom Chemical group 0.000 description 7
230000000903 blocking effect Effects 0.000 description 7
238000004364 calculation method Methods 0.000 description 7
238000009833 condensation Methods 0.000 description 7
230000005494 condensation Effects 0.000 description 7
230000008878 coupling Effects 0.000 description 7
230000006378 damage Effects 0.000 description 7
201000010099 disease Diseases 0.000 description 7
208000037765 diseases and disorders Diseases 0.000 description 7
238000002513 implantation Methods 0.000 description 7
238000002156 mixing Methods 0.000 description 7
239000003607 modifier Substances 0.000 description 7
150000007523 nucleic acids Chemical class 0.000 description 7
230000003647 oxidation Effects 0.000 description 7
238000007254 oxidation reaction Methods 0.000 description 7
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
239000002904 solvent Substances 0.000 description 7
238000001228 spectrum Methods 0.000 description 7
IDDDVXIUIXWAGJ-DDSAHXNVSA-N 4-[(1r)-1-aminoethyl]-n-pyridin-4-ylcyclohexane-1-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IDDDVXIUIXWAGJ-DDSAHXNVSA-N 0.000 description 6
208000024827 Alzheimer disease Diseases 0.000 description 6
241000283707 Capra Species 0.000 description 6
101800001318 Capsid protein VP4 Proteins 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
208000018737 Parkinson disease Diseases 0.000 description 6
208000006011 Stroke Diseases 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
230000004913 activation Effects 0.000 description 6
150000002148 esters Chemical class 0.000 description 6
125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
239000003590 rho kinase inhibitor Substances 0.000 description 6
239000007787 solid Substances 0.000 description 6
238000001551 total correlation spectroscopy Methods 0.000 description 6
238000002424 x-ray crystallography Methods 0.000 description 6
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 5
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
101150111584 RHOA gene Proteins 0.000 description 5
238000013459 approach Methods 0.000 description 5
229920001222 biopolymer Polymers 0.000 description 5
238000003776 cleavage reaction Methods 0.000 description 5
210000002950 fibroblast Anatomy 0.000 description 5
230000004927 fusion Effects 0.000 description 5
108020001507 fusion proteins Proteins 0.000 description 5
102000037865 fusion proteins Human genes 0.000 description 5
239000012528 membrane Substances 0.000 description 5
238000000302 molecular modelling Methods 0.000 description 5
210000005036 nerve Anatomy 0.000 description 5
238000003522 neurite outgrowth assay Methods 0.000 description 5
230000007935 neutral effect Effects 0.000 description 5
102000039446 nucleic acids Human genes 0.000 description 5
108020004707 nucleic acids Proteins 0.000 description 5
238000010647 peptide synthesis reaction Methods 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
230000009257 reactivity Effects 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
230000002441 reversible effect Effects 0.000 description 5
230000007017 scission Effects 0.000 description 5
230000019491 signal transduction Effects 0.000 description 5
125000006850 spacer group Chemical group 0.000 description 5
230000009469 supplementation Effects 0.000 description 5
239000000725 suspension Substances 0.000 description 5
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 4
108010016626 Dipeptides Proteins 0.000 description 4
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 4
108091028043 Nucleic acid sequence Proteins 0.000 description 4
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 4
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 4
206010035226 Plasma cell myeloma Diseases 0.000 description 4
239000002253 acid Substances 0.000 description 4
150000001540 azides Chemical class 0.000 description 4
230000008901 benefit Effects 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
238000010511 deprotection reaction Methods 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
239000012636 effector Substances 0.000 description 4
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
229940088597 hormone Drugs 0.000 description 4
239000005556 hormone Substances 0.000 description 4
210000004408 hybridoma Anatomy 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
230000003278 mimic effect Effects 0.000 description 4
201000000050 myeloid neoplasm Diseases 0.000 description 4
230000001537 neural effect Effects 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
210000004248 oligodendroglia Anatomy 0.000 description 4
229960003104 ornithine Drugs 0.000 description 4
239000007800 oxidant agent Substances 0.000 description 4
238000003752 polymerase chain reaction Methods 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
125000006239 protecting group Chemical group 0.000 description 4
230000008929 regeneration Effects 0.000 description 4
238000011069 regeneration method Methods 0.000 description 4
238000004007 reversed phase HPLC Methods 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
239000000758 substrate Substances 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
102000015533 trkA Receptor Human genes 0.000 description 4
108010064884 trkA Receptor Proteins 0.000 description 4
238000005084 2D-nuclear magnetic resonance Methods 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
239000004471 Glycine Substances 0.000 description 3
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
ZHEHVZXPFVXKEY-RUAOOFDTSA-N KT 5720 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@@H]1C[C@](C(=O)OCCCCCC)(O)[C@@]4(C)O1 ZHEHVZXPFVXKEY-RUAOOFDTSA-N 0.000 description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
239000012828 PI3K inhibitor Substances 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
208000030886 Traumatic Brain injury Diseases 0.000 description 3
238000006640 acetylation reaction Methods 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
238000001042 affinity chromatography Methods 0.000 description 3
150000008064 anhydrides Chemical class 0.000 description 3
239000011324 bead Substances 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000006227 byproduct Substances 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000001311 chemical methods and process Methods 0.000 description 3
238000002884 conformational search Methods 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
229940039227 diagnostic agent Drugs 0.000 description 3
239000000032 diagnostic agent Substances 0.000 description 3
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
206010015037 epilepsy Diseases 0.000 description 3
239000003102 growth factor Substances 0.000 description 3
230000001771 impaired effect Effects 0.000 description 3
230000006872 improvement Effects 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
229940043355 kinase inhibitor Drugs 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
238000000329 molecular dynamics simulation Methods 0.000 description 3
230000000926 neurological effect Effects 0.000 description 3
230000001590 oxidative effect Effects 0.000 description 3
125000001151 peptidyl group Chemical class 0.000 description 3
229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 3
239000003757 phosphotransferase inhibitor Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
229940043437 protein kinase A inhibitor Drugs 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000006340 racemization Effects 0.000 description 3
102000000568 rho-Associated Kinases Human genes 0.000 description 3
108010041788 rho-Associated Kinases Proteins 0.000 description 3
230000001953 sensory effect Effects 0.000 description 3
238000004088 simulation Methods 0.000 description 3
238000001179 sorption measurement Methods 0.000 description 3
210000000278 spinal cord Anatomy 0.000 description 3
238000011200 topical administration Methods 0.000 description 3
230000009529 traumatic brain injury Effects 0.000 description 3
230000000007 visual effect Effects 0.000 description 3
238000011179 visual inspection Methods 0.000 description 3
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
VRVRGVPWCUEOGV-UHFFFAOYSA-N 2-aminothiophenol Chemical compound NC1=CC=CC=C1S VRVRGVPWCUEOGV-UHFFFAOYSA-N 0.000 description 2
GSWYUZQBLVUEPH-UHFFFAOYSA-N 3-(azaniumylmethyl)benzoate Chemical compound NCC1=CC=CC(C(O)=O)=C1 GSWYUZQBLVUEPH-UHFFFAOYSA-N 0.000 description 2
206010001258 Adenoviral infections Diseases 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
241000195493 Cryptophyta Species 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
239000003155 DNA primer Substances 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
108091008794 FGF receptors Proteins 0.000 description 2
206010018341 Gliosis Diseases 0.000 description 2
108010024636 Glutathione Proteins 0.000 description 2
206010019196 Head injury Diseases 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
101100281008 Homo sapiens FGF2 gene Proteins 0.000 description 2
101001090172 Homo sapiens Kinectin Proteins 0.000 description 2
101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 description 2
208000023105 Huntington disease Diseases 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
108091092195 Intron Proteins 0.000 description 2
102100034751 Kinectin Human genes 0.000 description 2
102000004856 Lectins Human genes 0.000 description 2
108090001090 Lectins Proteins 0.000 description 2
102000008072 Lymphokines Human genes 0.000 description 2
108010074338 Lymphokines Proteins 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 2
102000005781 Nogo Receptor Human genes 0.000 description 2
108020003872 Nogo receptor Proteins 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
206010038997 Retroviral infections Diseases 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 2
230000021736 acetylation Effects 0.000 description 2
238000007083 alkoxycarbonylation reaction Methods 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
238000007112 amidation reaction Methods 0.000 description 2
125000003368 amide group Chemical group 0.000 description 2
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
125000002619 bicyclic group Chemical group 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
238000006664 bond formation reaction Methods 0.000 description 2
239000007975 buffered saline Substances 0.000 description 2
238000004422 calculation algorithm Methods 0.000 description 2
239000002775 capsule Substances 0.000 description 2
150000001718 carbodiimides Chemical class 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
239000013553 cell monolayer Substances 0.000 description 2
230000015861 cell surface binding Effects 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
238000007621 cluster analysis Methods 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
239000003527 fibrinolytic agent Substances 0.000 description 2
230000003480 fibrinolytic effect Effects 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000008103 glucose Substances 0.000 description 2
229960003180 glutathione Drugs 0.000 description 2
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
208000014674 injury Diseases 0.000 description 2
210000001153 interneuron Anatomy 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000007917 intracranial administration Methods 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
150000003951 lactams Chemical class 0.000 description 2
150000002605 large molecules Chemical group 0.000 description 2
239000002523 lectin Substances 0.000 description 2
239000002502 liposome Substances 0.000 description 2
239000007791 liquid phase Substances 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
238000012900 molecular simulation Methods 0.000 description 2
230000037023 motor activity Effects 0.000 description 2
SHDMMLFAFLZUEV-UHFFFAOYSA-N n-methyl-1,1-diphenylmethanamine Chemical compound C=1C=CC=CC=1C(NC)C1=CC=CC=C1 SHDMMLFAFLZUEV-UHFFFAOYSA-N 0.000 description 2
230000009223 neuronal apoptosis Effects 0.000 description 2
239000000346 nonvolatile oil Substances 0.000 description 2
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
230000000269 nucleophilic effect Effects 0.000 description 2
238000005457 optimization Methods 0.000 description 2
LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 description 2
210000001428 peripheral nervous system Anatomy 0.000 description 2
235000019271 petrolatum Nutrition 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
230000035790 physiological processes and functions Effects 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
108091033319 polynucleotide Proteins 0.000 description 2
102000040430 polynucleotide Human genes 0.000 description 2
239000002157 polynucleotide Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
230000005855 radiation Effects 0.000 description 2
229940075993 receptor modulator Drugs 0.000 description 2
238000011160 research Methods 0.000 description 2
230000001177 retroviral effect Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
102000011843 rho-Specific Guanine Nucleotide Dissociation Inhibitors Human genes 0.000 description 2
108010036036 rho-Specific Guanine Nucleotide Dissociation Inhibitors Proteins 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000000523 sample Substances 0.000 description 2
230000035807 sensation Effects 0.000 description 2
238000007086 side reaction Methods 0.000 description 2
238000002922 simulated annealing Methods 0.000 description 2
238000010532 solid phase synthesis reaction Methods 0.000 description 2
210000004989 spleen cell Anatomy 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000013589 supplement Substances 0.000 description 2
230000001629 suppression Effects 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000002889 sympathetic effect Effects 0.000 description 2
150000003568 thioethers Chemical class 0.000 description 2
210000000115 thoracic cavity Anatomy 0.000 description 2
108010064892 trkC Receptor Proteins 0.000 description 2
102000047459 trkC Receptor Human genes 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
102000003390 tumor necrosis factor Human genes 0.000 description 2
239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
238000001363 water suppression through gradient tailored excitation Methods 0.000 description 2
210000005253 yeast cell Anatomy 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
APQIUTYORBAGEZ-UHFFFAOYSA-N 1,1-dibromoethane Chemical compound CC(Br)Br APQIUTYORBAGEZ-UHFFFAOYSA-N 0.000 description 1
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
101710175516 14 kDa zinc-binding protein Proteins 0.000 description 1
BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical compound CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 description 1
YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
HBAHZZVIEFRTEY-UHFFFAOYSA-N 2-heptylcyclohex-2-en-1-one Chemical compound CCCCCCCC1=CCCCC1=O HBAHZZVIEFRTEY-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
241000271566 Aves Species 0.000 description 1
102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 1
108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 1
WBTZXPNXXYXRQB-UHFFFAOYSA-N CCC1c2ccccc2NC1SCC Chemical compound CCC1c2ccccc2NC1SCC WBTZXPNXXYXRQB-UHFFFAOYSA-N 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000012422 Collagen Type I Human genes 0.000 description 1
108010022452 Collagen Type I Proteins 0.000 description 1
241000938605 Crocodylia Species 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 description 1
101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
241000764238 Isis Species 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
229920001367 Merrifield resin Polymers 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
238000000342 Monte Carlo simulation Methods 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
101800005149 Peptide B Proteins 0.000 description 1
229940083963 Peptide antagonist Drugs 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
GLUBLISJVJFHQS-VIFPVBQESA-N Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 GLUBLISJVJFHQS-VIFPVBQESA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
229940123924 Protein kinase C inhibitor Drugs 0.000 description 1
238000004617 QSAR study Methods 0.000 description 1
230000010799 Receptor Interactions Effects 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
206010040030 Sensory loss Diseases 0.000 description 1
229920001872 Spider silk Polymers 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
241000269370 Xenopus <genus> Species 0.000 description 1
206010000059 abdominal discomfort Diseases 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
125000002015 acyclic group Chemical group 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
150000001295 alanines Chemical class 0.000 description 1
125000003172 aldehyde group Chemical group 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
235000008206 alpha-amino acids Nutrition 0.000 description 1
125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
238000010976 amide bond formation reaction Methods 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
238000003277 amino acid sequence analysis Methods 0.000 description 1
238000007098 aminolysis reaction Methods 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
229940035674 anesthetics Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000954 anitussive effect Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000000507 anthelmentic effect Effects 0.000 description 1
229940124339 anthelmintic agent Drugs 0.000 description 1
239000000921 anthelmintic agent Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
239000004004 anti-anginal agent Substances 0.000 description 1
230000002456 anti-arthritic effect Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000002460 anti-migrenic effect Effects 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
230000002365 anti-tubercular Effects 0.000 description 1
229940124345 antianginal agent Drugs 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000000729 antidote Substances 0.000 description 1
229940075522 antidotes Drugs 0.000 description 1
229940125683 antiemetic agent Drugs 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
239000003430 antimalarial agent Substances 0.000 description 1
229940033495 antimalarials Drugs 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
239000004019 antithrombin Substances 0.000 description 1
229940124584 antitussives Drugs 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
239000002830 appetite depressant Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
FEMYXXCBVRPCFV-UHFFFAOYSA-N benzenesulfinylbenzene;trichloro(methyl)silane Chemical compound C[Si](Cl)(Cl)Cl.C=1C=CC=CC=1S(=O)C1=CC=CC=C1 FEMYXXCBVRPCFV-UHFFFAOYSA-N 0.000 description 1
RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
238000005574 benzylation reaction Methods 0.000 description 1
235000021028 berry Nutrition 0.000 description 1
150000001576 beta-amino acids Chemical class 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
239000012867 bioactive agent Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
230000003185 calcium uptake Effects 0.000 description 1
BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000003554 cannabinoid 1 receptor agonist Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000007942 carboxylates Chemical group 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
210000000782 cerebellar granule cell Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000012881 co-culture medium Substances 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000000512 collagen gel Substances 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
238000005100 correlation spectroscopy Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
238000013500 data storage Methods 0.000 description 1
238000001804 debridement Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
230000005347 demagnetization Effects 0.000 description 1
NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
229960004281 desmopressin Drugs 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000010586 diagram Methods 0.000 description 1
VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
239000003989 dielectric material Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000002050 diffraction method Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
229940043279 diisopropylamine Drugs 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000009881 electrostatic interaction Effects 0.000 description 1
239000008387 emulsifying waxe Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000005281 excited state Effects 0.000 description 1
239000003172 expectorant agent Substances 0.000 description 1
230000003419 expectorant effect Effects 0.000 description 1
229940066493 expectorants Drugs 0.000 description 1
238000000605 extraction Methods 0.000 description 1
XPYGGHVSFMUHLH-UUSULHAXSA-N falecalcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(O)(C(F)(F)F)C(F)(F)F)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C XPYGGHVSFMUHLH-UUSULHAXSA-N 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
229910052733 gallium Inorganic materials 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
LEZNRPFLOGYEIO-QSEDPUOVSA-N ganglioside GT1b Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@@H](CO)O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@]4(O[C@H]([C@H](NC(C)=O)[C@@H](O)C4)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 LEZNRPFLOGYEIO-QSEDPUOVSA-N 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
210000000020 growth cone Anatomy 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
239000007952 growth promoter Substances 0.000 description 1
230000002439 hemostatic effect Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
102000046917 human NGF Human genes 0.000 description 1
WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
229940091173 hydantoin Drugs 0.000 description 1
150000001261 hydroxy acids Chemical class 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
239000003326 hypnotic agent Substances 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
238000010185 immunofluorescence analysis Methods 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000004041 inotropic agent Substances 0.000 description 1
230000010354 integration Effects 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
230000001788 irregular Effects 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
239000008141 laxative Substances 0.000 description 1
230000002475 laxative effect Effects 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
231100000782 microtubule inhibitor Toxicity 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
238000000324 molecular mechanic Methods 0.000 description 1
238000013425 morphometry Methods 0.000 description 1
239000003887 narcotic antagonist Substances 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
230000009689 neuronal regeneration Effects 0.000 description 1
230000000508 neurotrophic effect Effects 0.000 description 1
239000003900 neurotrophic factor Substances 0.000 description 1
229940032018 neurotrophin 3 Drugs 0.000 description 1
229940097998 neurotrophin 4 Drugs 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000012585 nuclear overhauser effect spectroscopy experiment Methods 0.000 description 1
239000002674 ointment Substances 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
238000005009 overhauser spectroscopy Methods 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
239000000734 parasympathomimetic agent Substances 0.000 description 1
230000001499 parasympathomimetic effect Effects 0.000 description 1
229940005542 parasympathomimetics Drugs 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
238000004810 partition chromatography Methods 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000000810 peripheral vasodilating agent Substances 0.000 description 1
229960002116 peripheral vasodilator Drugs 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
239000002574 poison Substances 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920005990 polystyrene resin Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000013630 prepared media Substances 0.000 description 1
230000037452 priming Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
239000012656 protein kinase A inhibitor Substances 0.000 description 1
239000003881 protein kinase C inhibitor Substances 0.000 description 1
108010065251 protein kinase modulator Proteins 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
108091006082 receptor inhibitors Proteins 0.000 description 1
102000027426 receptor tyrosine kinases Human genes 0.000 description 1
108091008598 receptor tyrosine kinases Proteins 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000009719 regenerative response Effects 0.000 description 1
230000007363 regulatory process Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000013341 scale-up Methods 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
239000011232 storage material Substances 0.000 description 1
229910052712 strontium Inorganic materials 0.000 description 1
CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
238000005556 structure-activity relationship Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
230000001975 sympathomimetic effect Effects 0.000 description 1
229940064707 sympathomimetics Drugs 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
229910052713 technetium Inorganic materials 0.000 description 1
GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
NBRKLOOSMBRFMH-UHFFFAOYSA-N tert-butyl chloride Chemical group CC(C)(C)Cl NBRKLOOSMBRFMH-UHFFFAOYSA-N 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000007070 tosylation reaction Methods 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1
QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Investigating Or Analysing Biological Materials (AREA)

JP2006526381A 2003-09-10 2004-09-10 ニューロンの成長を調節する化合物およびそれらの使用 Expired - Fee Related JP4944611B2 (ja)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US50186403P	2003-09-10	2003-09-10
US60/501,864		2003-09-10
US55989804P	2004-04-05	2004-04-05
US60/559,898		2004-04-05
US60318704P	2004-08-20	2004-08-20
US60/603,187		2004-08-20
PCT/US2004/029888 WO2005025514A2 (en)	2003-09-10	2004-09-10	Compounds that modulate neuronal growth and their uses

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2010235591A Division JP2011057685A (ja)	2003-09-10	2010-10-20	ニューロンの成長を調節する化合物およびそれらの使用

Publications (3)

Publication Number	Publication Date
JP2007505145A JP2007505145A (ja)	2007-03-08
JP2007505145A5 JP2007505145A5 (2)	2007-06-07
JP4944611B2 true JP4944611B2 (ja)	2012-06-06

Family

ID=34317473

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2006526381A Expired - Fee Related JP4944611B2 (ja)	2003-09-10	2004-09-10	ニューロンの成長を調節する化合物およびそれらの使用
JP2010235591A Pending JP2011057685A (ja)	2003-09-10	2010-10-20	ニューロンの成長を調節する化合物およびそれらの使用

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2010235591A Pending JP2011057685A (ja)	2003-09-10	2010-10-20	ニューロンの成長を調節する化合物およびそれらの使用

Country Status (7)

Country	Link
US (1)	US7196061B2 (2)
EP (2)	EP2438925A3 (2)
JP (2)	JP4944611B2 (2)
AU (1)	AU2004272107B2 (2)
BR (1)	BRPI0414323A (2)
CA (1)	CA2535279A1 (2)
WO (1)	WO2005025514A2 (2)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102005004343A1 (de) *	2005-01-25	2006-08-10	Eberhard-Karls-Universität Tübingen Universitätsklinikum	Behandlung von Phantomphänomenen
WO2006130781A2 (en) *	2005-06-01	2006-12-07	The Scripps Research Institute	Crystal of a cytochrome-ligand complex and methods of use
US8195021B2 (en)	2006-11-03	2012-06-05	Tufts University/Trustees Of Tufts College	Biopolymer optical waveguide and method of manufacturing the same
US8529835B2 (en) *	2006-11-03	2013-09-10	Tufts University	Biopolymer sensor and method of manufacturing the same
JP2010509645A (ja)	2006-11-03	2010-03-25	トラスティーズオブタフツカレッジ	ナノパターンが形成されたバイオポリマー光学デバイスおよびその製造方法
JP2011231085A (ja) *	2010-04-30	2011-11-17	Osaka Prefecture Univ	環状ペプチド
WO2016146730A1 (en) *	2015-03-19	2016-09-22	Neuheart S.R.L.	PEPTIDES HAVING TrkA-RECEPTOR-AGONISTIC ACTIVITY OR HAVING NGF-ANTAGONISTIC ACTIVITY
CN113993880A (zh) *	2019-06-11	2022-01-28	富士胶片株式会社	环肽、细胞支架材料、细胞分离材料及培养基
WO2021256619A1 (ko) *	2020-06-18	2021-12-23	연세대학교 산학협력단	시냅스 가소성 조절 기능의 펩타이드를 포함하는 인지기능 장애 질환의 예방, 개선 또는 치료용 조성물
US20230312651A1 (en) *	2020-07-10	2023-10-05	The University Of Tokyo	Cyclic Peptide, Peptide Complex, and Drug Composition Containing Said Cyclic Peptide and/or Said Peptide Complex

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5079600A (en)	1987-03-06	1992-01-07	Schnur Joel M	High resolution patterning on solid substrates
US5245012A (en)	1990-04-19	1993-09-14	The United States Of America As Represented By The Secretary Of The Army	Method to achieve solubilization of spider silk proteins
US5364769A (en)	1990-09-25	1994-11-15	Genentech, Inc.	Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production
US5981478A (en) *	1993-11-24	1999-11-09	La Jolla Cancer Research Foundation	Integrin-binding peptides
GB9402331D0 (en)	1994-02-07	1994-03-30	Univ Mcgill	Nerve growth factor structural analogs and their uses
US5844092A (en)	1994-03-18	1998-12-01	Genentech, Inc.	Human TRK receptors and neurotrophic factor inhibitors
US5877016A (en)	1994-03-18	1999-03-02	Genentech, Inc.	Human trk receptors and neurotrophic factor inhibitors
US5660848A (en)	1994-11-02	1997-08-26	The Population Council, Center For Biomedical Research	Subdermally implantable device
CA2256543C (en) *	1996-05-31	2010-12-07	The Scripps Research Institute	Methods and compositions useful for inhibition of angiogenesis
US20020168761A1 (en)	2000-01-24	2002-11-14	Gour Barbara J.	Peptidomimetic modulators of cell adhesion
US6031072A (en)	1996-07-12	2000-02-29	Mcgill University	Compounds and methods for modulating cell adhesion
US6096707A (en) *	1997-07-11	2000-08-01	Biotie Therapies Ltd.	Integrin binding peptide and use thereof
HU229520B1 (en) *	1999-02-12	2014-01-28	Scripps Research Inst	Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
AU2001273245A1 (en) *	2000-07-05	2002-01-14	Pangene Corporation	Modulators of trk protein activity, compositions and uses

2004
- 2004-09-09 US US10/938,409 patent/US7196061B2/en not_active Expired - Fee Related
- 2004-09-10 EP EP11170573A patent/EP2438925A3/en not_active Withdrawn
- 2004-09-10 BR BRPI0414323-0A patent/BRPI0414323A/pt not_active IP Right Cessation
- 2004-09-10 WO PCT/US2004/029888 patent/WO2005025514A2/en not_active Ceased
- 2004-09-10 AU AU2004272107A patent/AU2004272107B2/en not_active Ceased
- 2004-09-10 JP JP2006526381A patent/JP4944611B2/ja not_active Expired - Fee Related
- 2004-09-10 EP EP04788721A patent/EP1663276A4/en not_active Withdrawn
- 2004-09-10 CA CA002535279A patent/CA2535279A1/en not_active Abandoned
2010
- 2010-10-20 JP JP2010235591A patent/JP2011057685A/ja active Pending

Also Published As

Publication number	Publication date
JP2011057685A (ja)	2011-03-24
WO2005025514A2 (en)	2005-03-24
AU2004272107B2 (en)	2011-04-07
EP1663276A2 (en)	2006-06-07
CA2535279A1 (en)	2005-03-24
US7196061B2 (en)	2007-03-27
EP1663276A4 (en)	2009-02-18
WO2005025514A3 (en)	2005-08-11
AU2004272107A1 (en)	2005-03-24
JP2007505145A (ja)	2007-03-08
BRPI0414323A (pt)	2006-11-07
US20050164920A1 (en)	2005-07-28
EP2438925A3 (en)	2012-08-29
EP2438925A2 (en)	2012-04-11

Legal Events

Date	Code	Title	Description
2007-04-10	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070409
2007-07-06	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070705
2010-04-21	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100420
2010-07-15	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100714
2010-07-23	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100722
2010-10-21	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101020
2010-12-01	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101130
2011-02-26	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110225
2011-03-07	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110304
2011-03-30	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110329
2011-04-06	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110405
2011-04-21	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110420
2011-04-28	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110427
2011-06-01	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110531
2011-09-14	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110913
2012-01-13	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120112
2012-01-23	A911	Transfer to examiner for re-examination before appeal (zenchi)	Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120120
2012-02-02	TRDD	Decision of grant or rejection written
2012-02-08	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120207
2012-02-09	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2012-03-08	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120302
2012-03-09	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150
2012-03-12	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20150309 Year of fee payment: 3
2015-03-09	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
JP2011057685A (ja)	2011-03-24	ニューロンの成長を調節する化合物およびそれらの使用
US7268115B2 (en)	2007-09-11	Peptidomimetic modulators of cell adhesion
US6110747A (en)	2000-08-29	Compounds and methods for modulating tissue permeability
US20040006011A1 (en)	2004-01-08	Peptidomimetic modulators of cell adhesion
US6291247B1 (en)	2001-09-18	Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity
US6169071B1 (en)	2001-01-02	Compounds and methods for modulating cell adhesion
US8603986B2 (en)	2013-12-10	Compounds and methods for modulating cadherin-mediated processes
JP2025011136A (ja)	2025-01-23	ジルコプランによる神経疾患治療
US20220251140A1 (en)	2022-08-11	Dpep-1 binding agents and methods of use
EP1734052B1 (en)	2009-02-18	Heterodimeric peptide compounds displaying NGF activity and their use to treat neurodegenerative disorders
CA2506037A1 (en)	2004-06-10	Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
Gisemba et al.	2021	Conformational constraint between aromatic residue side chains in the “message” sequence of the peptide arodyn using ring closing metathesis results in a potent and selective kappa opioid receptor antagonist
US7456153B2 (en)	2008-11-25	Compounds and methods for modulating functions of classical cadherins
US6207639B1 (en)	2001-03-27	Compounds and methods for modulating neurite outgrowth
US20080260829A1 (en)	2008-10-23	Bmp Gene and Fusion Protein
CN105263950A (zh)	2016-01-20	钉合eIF4E相互作用肽
CN1849132A (zh)	2006-10-18	调节神经元生长的化合物以及它们的用途
JP2003502295A (ja)	2003-01-21	脳由来神経栄養因子の小さな環状模擬体
HK1168049A (en)	2012-12-21	Compounds that modulate neuronal growth and their uses
MXPA06002557A (es)	2007-04-10	Compuestos que modulan el crecimiento neuronal y sus usos
BR112019024944A2 (pt)	2020-06-23	Subunidade auxilária de canal de cálcio com porta de tensão alfa 2 delta e suas utilizações